PharmaBharatPharma & Life Sciences Jobs
Menu

CLINICAL STUDY · NCT07859683

TMS + Exposure Therapy for Pediatric OCD: Second Phase

RecruitingNot applicableInterventional

Sponsored by Bradley Hospital

Condition
Obsessive Compulsive Behavior
Study locations
2 reported sites
Study updated
19 Oct 2026
Source
ClinicalTrials.gov

Overall study status is shown above. Individual hospitals may have a different recruitment status.

THE STUDY

About this study

The goal of this clinical trial is to test transcranial magnetic stimulation (TMS) for improving the outcomes of Exposure with Response Prevention (ERP) in youth and young adults with Obsessive-Compulsive Disorder (OCD). Researchers will compare two groups: ERP with active ("real") TMS vs. ERP with sham ("fake") TMS. The first phase of this study found that active TMS+ERP normalized functioning in brain circuits that contribute to compulsive behavior. This second phase will test whether TMS-induced brain changes lead to improvements in OCD symptom severity. Participants will:

* Complete clinical interviews, questionnaires, and computerized tasks
* Complete two MRIs (brain scans)
* Receive daily TMS followed by ERP for two weeks (10 sessions)
Full official title
Transcranial Magnetic Stimulation to Augment Exposure and Response Prevention for Pediatric OCD
Detailed description
Pediatric OCD is a public health problem and many remain symptomatic even after receiving efficacious treatments. The success of exposure and response prevention (ERP), a first-line behavioral treatment, depends on the ability to refrain from compulsions during exposure tasks. Improving this "therapy critical behavior" is a potentially important strategy for ERP augmentation. Repetitive transcranial magnetic stimulation (rTMS) can be leveraged to stimulate healthier functioning of brain circuits underlying therapy critical behaviors. The overall objective of this project is to test whether augmenting ERP with rTMS over cortical nodes of select cortico-striatal circuits implicated in compulsivity can normalize connectivity and enhance response prevention in youth and young adults with OCD. This project will use a masked RCT design to test whether ERP+TMS engages hypothesized circuits involved in compulsivity and whether this leads to clinical improvement. Youth ages 12-21 years with OCD will complete a full course of ERP plus randomly assigned TMS regimens of sham or continuous theta burst stimulation (cTBS) to the presupplementary motor area (pSMA; n=30 per group).

PARTICIPATION

Who may participate

Minimum age
12 Years
Maximum age
21 Years
Sex eligibility
All sexes
Healthy volunteers
Not accepted

Only the study team can confirm eligibility. The registry criteria below are not a medical recommendation.

Full inclusion and exclusion criteria
Inclusion Criteria:

* Between the ages of 12 and 21 years.
* Presence of OCD, as indicated by a score of \> 16 on the Children's Yale-Brown Obsessive Compulsive Scale, indicating moderate or greater OCD symptoms.
* Presence of motor compulsions on CY-BOCS compulsion checklist
* English fluency to ensure comprehension of informed consent and study measures and instructions.

Exclusion Criteria:

* Decline to provide informed consent.
* Has a personal history, or a family history in a first-born relative, of any medical or psychiatric disorder, disease, condition, injury, symptoms or circumstance that, in the opinion of the principal investigator, may: (1) impact the risk profile of TMS; (2) reduce the subject's ability to fulfill the study requirements as per protocol; or (3) adversely impact the integrity of the data or the validity of the study results." Some examples include: epilepsy or seizure disorder(s), bipolar disorder or any psychiatric disorder associated with a risk of mania, intracranial pathology, traumatic brain injury, brain tumor, stroke, implanted medical devices or metallic objects in the head, or moderate-severe heart disease
* Pregnant according to the medical history or a urine pregnancy test; and menstruating females who are heterosexually active and not using a highly effective form of contraception (tubal ligation, FDA-approved hormonal contraceptive, or an IUD)
* Inability to undergo MRI.
* Is deemed to be at imminent risk of suicide according to the Ask Suicide-Screening Questions (ASQ) (i.e. answers YES to ≥ one (1) of the four screening questions) and/or in the medical opinion of the investigator
* History of, or risk factors for, neurocardiogenic syncope (history of syncope/ presyncope related to noxious stimuli, anxiety, micturation, or posture).
* Concurrent psychotherapy of any kind for OCD.
* Concurrent TMS or receipt of any TMS experimental or clinical treatment less than 3 months prior to enrollment.
* Taking a medication deemed to pose high seizurogenic potential per physician review
* Taking a medication that has not reached stability criterion (same medication and dose for 6 weeks with no planned changes over the study period)

NEAR YOU

Study locations worldwide

2 sites

Check the individual site’s status and contact the listed study team for current availability.

University of Minnesota

Recruiting

Minneapolis, Minnesota, 55414, United States

Site contacts (1)
Christine Conelea, PhDContactPhone: 612-261-3127Email: cconelea@umn.edu

Emma Pendleton Bradley Hospital

Recruiting

Providence, Rhode Island, 02915, United States

Site contacts (1)
Kristen Benito, PhDContactPhone: 4014321054Email: kbenito@brownhealth.org

WHAT IS BEING STUDIED

Treatments and study groups

Interventions

Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor areaDevice
TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern

Study groups: ERP+cTBS

Other names: TMS, neuromodulation, cTBS

Transcranial Magnetic Stimulation: ShamDevice
Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex

Study groups: ERP+Sham

Other names: TMS, neuromodulation

Exposure with Response PreventionBehavioral
ERP will be delivered daily, immediately following TMS

Study groups: ERP+Sham, ERP+cTBS

Other names: ERP, Exposure Therapy, Cognitive Behavioral Therapy, CBT

Study groups

ERP+cTBSExperimental
Participants will receive two weeks (10 sessions) of continuous theta burst stimulation (cTBS; a form of TMS) targeting the presupplementary motor area (pSMA), followed immediately by Exposure Plus Response Prevention (ERP).

Interventions: Device: Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area, Behavioral: Exposure with Response Prevention

ERP+ShamActive comparator
Participants will receive two weeks (10 sessions) of sham ("fake") TMS, followed immediately by Exposure Plus Response Prevention (ERP).

Interventions: Device: Transcranial Magnetic Stimulation: Sham, Behavioral: Exposure with Response Prevention

RESEARCH DETAILS

Study design

Study type
Interventional
Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Study model
Parallel
Masking
Quadruple
Enrolment
60 participants · Estimated
Who is masked
Participant, Care provider, Investigator, Outcomes assessor

Study model details

Quadruple-masked Randomized Controlled Trial (RCT) with parallel assignment

TIMELINE & MEASURES

Dates and outcomes

Study started
31 Oct 2026 · Estimated
Primary completion
31 Aug 2029 · Estimated
Study completion
31 Oct 2029 · Estimated
First registered
6 Oct 2026 · Actual
Last registry update
19 Oct 2026 · Actual
Status last verified
Oct 2026
Primary outcomes (3)

Functional Magnetic Resonance Imaging (fMRI): connectivity of the pSMA-DLS circuit

correlation coefficient representing resting state connectivity between presupplementary motor area (pSMA) and dorsolateral striatum (DLS)

Time frame: two weeks (post-treatment)

Observed Compulsive Behavior

Duration of time during which compulsions are observed during ERP sessions

Time frame: two weeks

Child/Adult Yale-Brown Obsessive Compulsive Inventory

Independent-Evaluator (IE) rated measure of OCD symptom severity. Rated on 0 (no symptoms) to 40 (most extreme symptoms) scale

Time frame: six weeks (1-month follow-up)

Secondary outcomes (1)

Clinical Global Impressions Scale-Improvement

Independent-Evaluator (IE) rated measure of clinical improvement. Rated on 1 (very much improved) to 7 (very much worse) scale

Time frame: six weeks (1-month follow-up)

STUDY TEAM

Sponsor and contacts

Lead sponsor
Bradley Hospital
Sponsor type
Other
Collaborators
University of Minnesota, Butler Hospital
Organisation study ID
2113426

Central study contacts

Kristen Benito, PhDContactPhone: 4014321054Email: kbenito@brownhealth.org
Study officials
Kristen Benito, PhDPrincipal investigator · Emma Pendleton Bradley Hospital
Christine ConeleaPrincipal investigator · University of Minnesota

Contacts are provided by the registry for study enquiries. Do not use these details for marketing or promotions.

FURTHER READING

Results, documents and references

No results are posted in this registry record

This does not mean the study has no findings. Results may not yet have been submitted or published here.

No study documents are listed in this record.

Source: ClinicalTrials.gov · Data fetched 20 Oct 2026, 15:02 GMT+0530

Registry data timestamp: 2026-10-19T09:00:04

Registry content is reformatted for readability; original study text is not rewritten. Missing information is labelled “Not reported”. Records are supplied by study sponsors or investigators and can change.

ClinicalTrials.gov does not endorse PharmaBharat. Listing a study does not mean it has been evaluated or approved by a government agency. Information is for research awareness and is not medical advice. Data source terms · Registry disclaimer